Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Allakos Inc
Healthcare
P/NCAV
0.87x
Ticker
ALLK
Exchange
NASDAQ
Country
United States
Close
1.05 $
Mkt Cap
91.1M $
EV
24.7M $
NCAV Burn Rate
54.9%
Current Ratio
4.92
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
-0.1x
EV/FCF
-0.2x
Dilution
11.5% p.A
Total Net Income
-1.1B $
Cheapness
99.0%
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The Company is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average